Product Description
SMP-3124 is an injection, a liposomally encapsulated CHK1 (checkpoint kinase 1) inhibitor. CHK1 is activated by DNA damage response, then arrests the cell cycle, and induces DNA repair via serine-threonine kinase. CHK1 inhibition leads cancer cell with high replication stress to apoptosis by inducing further DNA damages. SMP-3124 is expected to strengthen the anti-tumor activity and weaken side effects by changing pharmacokinetics of the compound with liposomal nanomedicinal encapsulation. (Sourced from: https://www.sumitomo-pharma.com/rd/pipeline_new-medicine/pipeline_profile.html)
Mechanisms of Action: CHK1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sumitomo Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|